Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352: 837-853

Patel, A, MacMahon, S, Chalmers, J. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358: 2560-2572

Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002; 287: 2563-2569

Standards of medical care in diabetes–2009. Diabetes Care. 2009; 32 (Suppl 1): S13-S61

Rodbard, HW, Blonde, L, Braithwaite, S. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007; 13 (suppl 1): 1-68

Nathan, DM, Buse, JB, Davidson, MB. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009; 32: 193-203

Woerle, HJ, Neumann, C, Zschau, S. Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes: importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract. 2007; 77: 280-285

Malmberg, K, Rydén, L, Wedel, H. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J. 2005; 26: 650-661

Dale, AC, Vatten, LJ, Nilsen, TI, Midthjell, K, Wiseth, R. Secular decline in mortality from coronary heart disease in adults with diabetes mellitus: cohort study. BMJ. 2008; 337: a236

Yusuf, S, Hawken, S, Ôunpuu, S. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004; 364: 937-952